The safety and efficacy of incobotulinumtoxinA in aesthetics has been established in multiple studies. Although individual studies have been reported, a combined assessment of incobotulinumtoxinA safety across studies is not available.
To assess the frequency of adverse events (AEs) across prospective incobotulinumtoxinA studies in aesthetics.
Safety data were assessed from 9 placebo-controlled or active-controlled single-dose studies on glabellar frown lines (GFL), crow's feet (CF), and upper facial lines (UFL). Analyses by treatment cycle included 4 repeat-dose studies on GFL and UFL.
One thousand three hundred seventy-seven subjects received incobotulinumtoxinA (GFL, n = 1,189; CF, n = 83; UFL, n = 105) in single-dose studies (placebo-controlled studies: incobotulinumtoxinA, n = 866; placebo, n = 395). Over 1,000 subjects received incobotulinumtoxinA in repeat-dose studies (GFL, n = 880; UFL, n = 290). In placebo-controlled single-dose studies, incidences of treatment-related AEs ranged from 5.4% (GFL) to 22.9% (UFL). The most frequent treatment-related AE in single-dose studies was headache (GFL, 4.8%; UFL, 11.4%). In repeat-dose studies, incidence of AEs was highest during cycle 1 (GFL, 8.9%; UFL, 17.2%) and decreased across treatment cycles. No serious treatment-related AEs were observed.
Results confirm the favorable safety and tolerability of incobotulinumtoxinA. The frequency of treatment-related AEs was low and may decrease with subsequent treatments.
*Coleman Cosmetic Dermatologic Surgery Center, Metairie, Louisiana;
†Rosenpark Klinik, Darmstadt, Germany;
‡Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany;
§Merz North America, Inc., Raleigh, North Carolina
Address correspondence and reprint requests to: Michael A. Hast, PhD, Merz North America, Inc., 6501 Six Forks Road, Raleigh, NC 27615, or e-mail: firstname.lastname@example.org
W.P. Coleman III and G. Sattler have been consultants and/or investigators for Merz. P. Weissenberger and A. Hanschmann are employees of Merz Pharmaceuticals GmbH. M.A. Hast is an employee of Merz North America, Inc.